women hinge on knowledge of antimicrobial susceptibility patterns in the geographic region of the practitioner. We conducted a survey of antimicrobial susceptibilities of 103,223 isolates recovered from urine samples that were obtained in 1998 from female outpatients nationally and within 9 geographic regions in the United States. Resistance of Escherichia coli isolates to trimethoprim-sulfamethoxazole varied significantly according to geographic region, ranging from a high of 22% in the western United States to a low of 10% in the Northeast ( ). There were no clinically significant age-related differences in the susceptibility of E. coli to any of P ! .001 the study drugs, but the susceptibility to fluoroquinolones of non-E. coli isolates that were recovered from women who were aged 150 years was significantly lower than that of isolates recovered from younger women ( ). The in vitro susceptibility of uropathogens in female outpatients varies according to age and P ! .001 geographic region.
The Infectious Diseases Society of America (IDSA) recently published guidelines for the treatment of women with community-acquired urinary tract infections (UTIs) that are based in part on the rate of resistance to trimethoprim-sulfamethoxazole (TMP-SMZ) in the geographic region of the practitioner [1] . However, as the authors of the guidelines acknowledge, such data are not always readily available in many areas. Although we and others have recently reported increasing antimicrobial resistance rates among uropathogens that cause acute cystitis in women [2] [3] [4] , these studies have been conducted within a single institution or a defined geographic area. Furthermore, many studies do not distinguish between urinary isolates that have been recovered from adult female outpatients (most of whom have uncomplicated UTIs) and those that have been recovered from men, children, or inpatients (most of whom have complicated UTIs). To address these issues, we used a national laboratory database to assess the rates of resistance among uropathogens that were recovered from female outpatients both nationally and within 9 geographic regions in the United States.
METHODS

Data collection.
The data presented here were ob- Klebsiella species 6 12 Proteus species 4 6
Enterobacter species 2 2
Pseudomonas aeruginosa 1 4
Other gram-negative rod 2 4
Enterococcus species 5 12
Staphylococcus aureus 2 2
Staphylococcus saprophyticus 2 0 . 2
Coagulase-negative staphylococci 3 2
Other 1 3
NOTE. There are significant differences in prevalence between age groups (P ! ) for all organisms with the exception of S. aureus, Enterobacter species, and .0001 coagulase-negative staphylococci.
a A total of 46,768 isolates were recovered from women aged 15-50 years and 56,455
isolates were recovered from women aged 150 years.
tained from The Surveillance Network (TSN) Database-USA, a national surveillance system that collects antimicrobial susceptibility results from clinical microbiology laboratories in 9 geographic regions of the United States. The methods used for data collection, verification, and quality control for this database have been described in detail elsewhere [5] . In brief, all laboratories must pass an inspection prior to enrollment. Data from enrolled laboratories are sent electronically to the central database. Unusual antimicrobial susceptibility profiles are verified by repeated testing, and duplicate data received within 5 days with regard to the same specimen source in a given patient are excluded. In order to limit our analyses to episodes of communityacquired UTI in women, including those UTIs that are most amenable to empirical therapy, the database was searched for isolates recovered from urine samples that were obtained from women aged 15-50 years and 150 years in an outpatient setting in 1998. Data from patients in nursing facilities were not included. Organisms that accounted for у2% of the total isolates within each age category were included in the study. Susceptibility patterns of other infrequently isolated organisms are not reported.
Laboratory methods. Antimicrobial susceptibility test results collected through TSN were generated by each of the TSN participant laboratories. All TSN laboratories use standard methods that comply with those published by the National Committee for Clinical Laboratory Standards [6] or with commercial methods approved by the US Food and Drug Administration. For this study, results regarding resistant isolates and intermediate susceptible isolates were combined.
Statistical methods. The proportion of resistant organisms was calculated by dividing the number of isolates that were resistant to each antimicrobial agent by the number of organisms that were tested against that antimicrobial agent. The main outcome of interest was the proportion of organisms that were resistant to each antimicrobial agent nationally and within the 9 geographic regions for patients in each age group. The significance of differences in resistance according to geographic region or age was determined by means of the x 2 test for independence [7] . Because of the extremely large number of isolates in the database, most differences in the prevalence of resistance that we tested were significant ( ), even if they varied by only 2%. P ! .05 Therefore, to make our results more meaningful for clinicians, we defined a variance of у10% as clinically significant and set our level of statistical significance at P ! .01.
RESULTS
A total of 103,223 isolates were recovered from urine samples obtained from female outpatients in 1998. The distribution of the pathogens according to age group is shown in Map showing that there is clinically significant (у10%) and statistically significant ( ) variation in the percentage of Escherichia P ! .001 coli isolates that were susceptible to trimethoprim-sulfamethoxazole (TMP-SMZ; white boxes) and ampicillin (dark boxes), in relation to geographic region and age group (15-50 years old vs. 150 years old), among strains that cause urinary tract infection in women who were treated on an outpatient basis.
women (
). Klebsiella pneumoniae, Enterococcus species, P ! .001 and Proteus mirabilis were the most common non-E. coli isolates in both age groups, but they were present in significantly higher proportions in women who were 150 years of age ( for each organism). Pseudomonas species, other gram-P ! .001 negative rods, and other organisms were also more frequently isolated from women who were 150 years of age ( for P ! .001 each organism). S. aureus, Enterobacter species, and coagulasenegative staphylococci accounted for 2%-3% of isolates recovered from women in each of the age groups.
The overall national susceptibilities of E. coli, non-E. coli, and all isolates combined, stratified by age group, are shown in table 2. Almost all E. coli isolates that were recovered from female outpatients were susceptible to nitrofurantoin and to the fluoroquinolones that were tested, regardless of age group. In contrast, 33%-40% of E. coli isolates were resistant to ampicillin and 16%-18% were resistant to TMP-SMZ in each age group. There were no clinically significant age-related differences in the susceptibility of E. coli to any of the drugs that were studied.
The non-E. coli isolates demonstrated higher resistance rates to each of the drugs that were studied with the exception of TMP-SMZ, which demonstrated in vitro activity against 82%-84% of E. coli isolates, versus 89%-94% of non-E. coli isolates. There was also a significant reduction in the percentage of non-E. coli isolates that were susceptible to the fluoroquinolones (range, 12%-16% reduction) in women who were 150 years of age, compared with data for the younger age group. When all isolates were considered together, susceptibility to the fluoroquinolones and nitrofurantoin was 190% in women who were 15-50 years of age but was somewhat lower (range, 8%-9% reduction) in women who were 150 years of age. Rates of susceptibility to TMP-SMZ and to ampicillin were similar between age groups for all isolates combined.
The overall prevalence of antimicrobial resistance among the non-E. coli species by age group is shown in table 3. Nitrofurantoin demonstrated the highest and most consistent activity against the gram-positive isolates, whereas the fluoroquinolones demonstrated the best activity against the non-E. coli, gramnegative isolates. There was a clinically significant, age-related variation in susceptibility of S. aureus and enterococci to the fluoroquinolones but for none of the other drugs that were studied.
The variation in rates of resistance of E. coli to ampicillin and TMP-SMZ, according to geographic region and age, is shown in figure 1 . There was not any clinically significant age- NOTE. The susceptibilities of coagulase-negative staphylococci that were not specifically identified as Staphylococcus saprophyticus and other rare organisms are not included. The reduction in susceptibility to nitrofurantoin and the fluoroquinolones among all isolates recovered from women who were 150 years of age was statistically significant ( ) but not clinically significant (see the Statistical Methods section). E. coli, Escherichia coli; TMP-P ! .001 SMZ, trimethoprim-sulfamethoxazole.
a Pseudomonas species were not tested.
b Enterococcus species were not tested.
related variation in resistance within each region for either of the antimicrobial agents. However, there was significant variation in susceptibility to both TMP-SMZ and ampicillin in relation to geographic region within each age group ( ). P ! .001 Susceptibility of E. coli isolates to TMP-SMZ was lowest in the western and southern regions of the United States, and it tended to increase in a northeasterly direction. This pattern was not observed with regard to susceptibility to ampicillin, although the lowest rates of susceptibility were observed in the southern regions. Overall, the 2 northeastern regions had the highest rates of susceptibility to both TMP-SMZ and ampicillin in comparison with the other regions. Susceptibility of E. coli to nitrofurantoin and to the fluoroquinolones did not vary according to geographic region (data not shown).
DISCUSSION
This study provides current information regarding the etiologic agents that cause community-acquired UTI in women in the outpatient setting and their antimicrobial susceptibility patterns in relation to age and geographic region on a national basis. By using this large national database and by restricting the analyses to female outpatients within these 2 age groups, we have defined the population that is most amenable to empirical therapy as recommended in the recently published IDSA guidelines. The safety and efficacy of such empirical therapy depends upon periodic assessment of antimicrobial resistance profiles.
The frequency distribution of etiologic organisms within each age group is quite consistent with the findings of previous, smaller studies of acute cystitis in women that were conducted in individual centers [8, 9] . E. coli and S. saprophyticus were more prevalent in younger women, whereas other gram-negative rods and enterococci were more prevalent in older women. Therefore, the agents that cause acute cystitis remain highly predictable, although they vary by age, even as the susceptibility patterns of these organisms change.
These data illustrate several important points regarding the drugs that are most frequently considered for empirical therapy for community-acquired UTI in women. First, rates of resistance to ampicillin range from 30% to 40% among E. coli and non-E. coli isolates nationwide. This resistance does not vary greatly by age group, either nationally or within each of the geographic regions that we studied. Although there is significant geographic variability in resistance to ampicillin, it is unacceptably high (у25%) throughout the United States. Therefore, as has been recommended by the IDSA and others [8] , ampicillin should be avoided in first-line therapy for patients with community-acquired UTIs.
Resistance to TMP-SMZ, the drug that was recommended for use as first-line therapy in the IDSA treatment guidelines, is ∼15% nationally in women in both age groups. However, rates of resistance of E. coli to this drug vary significantly according to geographic region, ranging from a high of 22% in the western United States to a low of 10% in the Northeast. Within regions, there is not much variation in rates of resistance to TMP-SMZ according to age group. Therefore, TMP-SMZ remains a reasonable first-line choice for empirical therapy in the northern and eastern states, although it may no longer be appropriate in western and southwestern states. Of note, a similar geographic distribution in TMP-SMZ resistance was recently reported by Talan et al. [10] among E. coli strains that cause acute pyelonephritis in a nationwide study.
How much variation there may be from locale to locale within each region cannot be readily ascertained from the database. The cause of this geographic variation in resistance to TMP-SMZ is also not apparent. One possibility could be re- gional differences in the use of TMP-SMZ as prophylaxis for patients with HIV infection or AIDS or for other uses. An alternative possibility could be introduction of TMP-SMZresistant strains into the western and southwestern United States from sources in Mexico or Asia, where markedly increased rates of resistance to TMP-SMZ are seen.
Alternative drugs that have been recommended by the IDSA for empirical treatment of patients with acute cystitis include fluoroquinolones and nitrofurantoin [1] . In general, resistance to the fluoroquinolones was minimal among women aged 15-50 years and did not vary by geographic region. Susceptibility to this class of drug was somewhat reduced among older women, mainly because of the resistance and higher prevalence of enterococci among women in this age group. Overall, the activity of fluoroquinolones was better than that of TMP-SMZ against all isolates combined in each age group; therefore, fluoroquinolones would be reasonable choices for empirical therapy in cases in which TMP-SMZ could not be used.
Nitrofurantoin also demonstrated activity against the majority of isolates that cause UTIs that were recovered from women aged 15-50 years. Older women were less likely to be infected with a strain susceptible to nitrofurantoin, mainly owing to the decreased activity of this drug against Proteus species and Klebsiella species, both of which are relatively more prevalent among women in this age group than they are among younger women. In general, the rates of susceptibility of isolates that were recovered from younger women to nitrofurantoin were better than the rates of susceptibility to TMP-SMZ; however, the isolates recovered from older women had equivalent rates of susceptibility to the 2 drugs.
In contrast to TMP-SMZ, however, susceptibility to nitrofurantoin did not differ by geographic region; therefore, this drug would be a reasonable alternative choice for therapy in areas where rates of resistance to TMP-SMZ are high. However, studies to date have demonstrated that 3-day regimens of nitrofurantoin have lower cure rates than do regimens of TMP-SMZ or fluoroquinolones [1, 11] , so a 7-day regimen is currently recommended [1] . Further studies of the efficacy of 3-day regimens of this drug would be of interest.
The extremely large database and the ability to define urinary isolates with regard to patient age, sex, region, and community versus nosocomial acquisition are major strengths of this study. The recently published IDSA guidelines make these data particularly relevant, because the guidelines provide practitioners with an estimate of susceptibility rates within well-defined geographic regions and patient groups. Local resistance patterns are clearly best when they are available, but they are increasingly not available because of the empirical treatment (without culture) of UTI in women.
The data do have certain limitations that are inherent to laboratory-based surveys. For example, because cultures are not performed for all empirically treated patients, unrecognized biases may cause physicians to obtain specimens for culture from some patients but not from others, thus influencing the susceptibility data that they obtain. In addition, although we have reported in vitro susceptibility data from those patients who are most likely to represent the population amenable to empirical therapy for cystitis (namely, adult women seen in the outpatient setting), we do not have specific data regarding the presence and nature of symptoms and signs or of complicating factors such as diabetes, recent hospitalization, catheterization, and urological or gynecologic surgery.
An unknown proportion of the women in the study undoubtedly had asymptomatic bacteriuria, complicated UTI, or pyelonephritis that was evaluated in the outpatient setting. However, the fact that the distribution of uropathogens and their rates of susceptibility are consistent with those from previous studies of women known to have acute uncomplicated cystitis suggests that the number of such cases is likely small. For example, the overall national rates of susceptibility for all isolates that were recovered from women who were 15-50 years of age in this study are very similar to the rates of susceptibility that we recently reported following a population-based study in Seattle in which we were able to specifically identify women with symptomatic acute uncomplicated cystitis and to exclude those with complicated UTI or pyelonephritis [2] . Likewise, the distribution of uropathogens is similar to that found in clinical trials of treatment of patients with acute uncomplicated cystitis [12] . Therefore, it is likely that the great majority of isolates included in our analyses were indeed recovered from patients who experienced episodes of acute uncomplicated cystitis.
Finally, it is important to note that the clinical significance of in vitro resistance in patients with uncomplicated cystitis has been little studied. McCarty et al. [13] found a 50% rate of bacterial eradication and a 60% rate of clinical cure among 10 women who were infected with a TMP-SMZ-resistant uropathogen and who had been randomized to receive treatment with TMP-SMZ. However, more studies are needed before definitive conclusions can be made regarding the implications of in vitro resistance in patients with cystitis. Certainly, factors such as clinical presentation, level of infection (upper vs. lower urinary tract), and cost need to be weighed in addition to prevalence of resistance when therapeutic agents are chosen.
In conclusion, the in vitro susceptibility of community-acquired uropathogens varies according to age and geographic region, even among adult women who were seen in the outpatient setting. This information needs to be considered when empirical therapy for acute cystitis is chosen. As the magnitude and variation of antimicrobial resistance in the community grow, so does the need for continuous large-scale surveillance systems such as TSN, which has yielded a database that can link epidemiological and clinical factors with laboratory results. In addition, studies of the clinical outcomes associated with in vitro resistance are needed. The more detailed the clinical and epidemiological data, the more precise the analyses that result can be. Clearly, continued surveillance is essential to maintaining the safety and cost-effectiveness of empirical therapy as a management strategy for acute cystitis.
